濮阳东方妇科口碑好价格低(濮阳东方医院男科治阳痿收费合理) (今日更新中)

BEIJING, Jan. 20 (Xinhua) -- China will regulate the production and sale of cosmetic colored contact lenses by including them in its list of items classified as "medical apparatus."Some people wear such non-corrective colored contacts to change or enhance eye color for cosmetic and fashion purposes.As these contacts are not for vision correction and medication purposes, they are currently off limits to the country's medical administration and regulators, said a statement published on the website of the State Food and Drug Administration on Thursday.However, with the increasingly popular use of cosmetic contacts, safety and quality problems due to the regulation loophole are likely to harm consumers' health, and the administration has decided to expand the current medical regulation on contact lenses to cover cosmetic ones, the statement said.It explained that the administration will soon issue a notice to ban the manufacture and sale of these contacts without proper registration and licenses.The statement also warned consumers of the risks of these contacts and suggested they carefully choose and use such products.

BEIJING, Oct. 27 (Xinhuanet) -- A new study shows that it's not simply a lack of willpower that explains weight regain but hormones keep one insisting on eating, a persistent biological urge. As any dieter knows, it's hard to keep weight off. Weight regain is a familiar problem for dieters. The research appears in Thursday's issue of the New England Journal of Medicine. To study what drives it, Proietto and his colleagues enrolled 50 overweight or obese patients in Australia in a 10-week diet program. On average, the participants lost almost 30 pounds in the 10 weeks - faster than the standard advice of losing a pound or two per week. Even so, they gained an average of 12 pounds back over the next year. The scientists checked the blood levels of nine hormones known to influence appetite - and found that even a year after the end of the weight-loss program, six of the hormones were still out of whack. People who regain weight should not be harsh on themselves, as eating is our most basic instinct, study author Joseph Proietto of the University of Melbourne in Australia said. It's better not to gain weight than to try to lose it.

WASHINGTON, Nov. 18 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday revoked its approval of Avastin for treating the breast cancer after concluding that the drug has not been shown to be safe and effective for that use.Avastin will still remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer."After reviewing the available studies it is clear that women who take Avastin for metastatic breast cancer risk potentially life-threatening side effects without proof that the use of Avastin will provide a benefit, in terms of delay in tumor growth, that would justify those risks," FDA Commissioner Margaret Hamburg said in a statement. "Nor is there evidence that use of Avastin will either help them live longer or improve their quality of life. "Avastin's risks include severe high blood pressure; bleeding and hemorrhaging; heart attack or heart failure; and the development of perforations in different parts of the body such as the nose, stomach, and intestines.Avastin was approved for metastatic breast cancer in February 2008 under the FDA's accelerated approval program, which allows a drug to be approved based on data that are not sufficiently complete to permit full approval. After the approval, the drug's sponsor, Genentech, completed two additional clinical trials and submitted the data from those studies to the FDA. These data showed only a small effect on tumor growth without evidence that patients lived any longer or had a better quality of life compared to taking standard chemotherapy alone -- not enough to outweigh the risk of taking the drug.FDA's Center for Drug Evaluation and Research, which is responsible for the approval of this drug, ultimately concluded that the results of these additional studies did not justify continued approval and notified Genentech it was proposing to withdraw approval of the indication.Genentech did not agree with the Center's evaluation of the data and, following the procedures set out in FDA regulations, requested a hearing on the Center's withdrawal proposal, with a decision to be made by the Commissioner. That two-day hearing, which took place June 28-29, included recommendations from the FDA 's Oncologic Drugs Advisory Committee, voting 6-0 in favor of withdrawing approval of Avastin's breast cancer indication.

BEIJING, Nov. 26 (Xinhua) -- Joint police patrols along the Mekong River will kick off in mid December to restore security after a deadly attack to Chinese ships in October.Chinese police will start patrols along the river with Laos, Myanmar and Thailand, said a statement from the Ministry of Public Security here Saturday.No exact date was given, but the first joint patrol will be carried out before Dec. 15, said the statement, issued after a ministerial meeting of four countries held in Beijing.Police from the four will work together to restore shipping and guarantee security along the river, the statement said.Shipping on the Mekong River has been suspended since two cargo ships were attacked on Oct. 5, resulting in the murder of 13 Chinese sailors.A headquarters for the initiative will be founded in China and there will be a coordination office in each of the other three countries. They will be linked by a round-the-clock communication mechanism, the statement said.China will assist Laos and Myanmar police in terms of training and equipment, the statement said.Police departments of the four countries will also set up a coordination team to work out more security measures along the Mekong River, it added.

WASHINGTON, Nov. 8 (Xinhua) -- NASA plans to add an unmanned flight test of the Orion spacecraft in early 2014 to its contract with Lockheed Martin Space Systems for the multipurpose crew vehicle's design, development, test and evaluation, the U.S. space agency announced Tuesday.This test supports the new Space Launch System (SLS) that will take astronauts farther into space than ever before, and provide the cornerstone for America's future human spaceflight efforts."President Obama and Congress have laid out an ambitious space exploration plan, and NASA is moving out quickly to implement it," NASA Associate Administrator for Communications David Weaver said in a statement. "This flight test will provide invaluable data to support the deep space exploration missions this nation is embarking upon."Orion is part of the now defunct Constellation program canceled under President Barack Obama's 2011 budget proposal. Instead Obama urged NASA to work toward sending humans to an asteroid and then on to Mars -- and NASA says it wants to go ahead with that as quickly as possible.This Exploration Flight Test, or EFT-1, will fly two orbits to a high-apogee, with a high-energy re-entry through Earth's atmosphere. Orion will make a water landing and be recovered using operations planned for future human exploration missions. The test mission will be launched from Cape Canaveral to acquire critical re-entry flight performance data and demonstrate early integration capabilities that benefit the Orion, SLS."The entry part of the test will produce data needed to develop a spacecraft capable of surviving speeds greater than 20,000 mph and safely return astronauts from beyond Earth orbit," Associate Administrator for Human Exploration and Operations William Gerstenmaier said. "This test is very important to the detailed design process in terms of the data we expect to receive."

来源：资阳报